Eventide Asset Management’s Vaxcyte PCVX Stock Holding History

Eventide Asset Management’s Portfolio PCVX Stock Details PCVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$79.8M	Buy	1,374,292 +457,177	+50%	+$24.8M	1.32%	15
2025 Q4	$42.3M	Buy	917,115 +537,785	+142%	+$24.1M	0.66%	53
2025 Q3	$13.7M	Sell	379,330 -468,811	-55%	-$15.5M	0.22%	116
2025 Q2	$27.6M	Buy	848,141 +377,911	+80%	+$12.4M	0.48%	76
2025 Q1	$17.8M	Buy	470,230 +86,776	+23%	+$6.94M	0.35%	92
2024 Q4	$31.4M	Hold	383,454	–	–	0.57%	58
2024 Q3	$43.8M	Sell	383,454 -355,699	-48%	-$32.1M	0.76%	45
2024 Q2	$55.8M	Buy	739,153 +81,947	+12%	+$5.58M	0.96%	33
2024 Q1	$44.9M	Buy	657,206 +50,000	+8%	+$3.46M	0.7%	53
2023 Q4	$38.1M	Buy	607,206 +214,206	+55%	+$11.1M	0.62%	55
2023 Q3	$20M	Buy	+393,000	New	+$19.4M	0.36%	83

Other funds holding PCVX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Eventide Asset Management's PCVX Position: Q1 2026 in Review

Eventide Asset Management increased its Vaxcyte (PCVX) stake by 50% in Q1 2026, buying an estimated $24.8M and bringing the position to 1,374,292 shares worth $79.8M. The position accounts for 1.32% of the portfolio, ranked #15.

Eventide Asset Management first reported a position in PCVX in Q3 2023 and has held it in 11 quarters since. 336 funds tracked by Wall St. Rank hold PCVX as of Q1 2026.

Eventide Asset Management held 1,374,292 shares of Vaxcyte worth $79.8M as of Q1 2026.
Eventide Asset Management bought 457,177 Vaxcyte shares in Q1 2026, an estimated $24.8M.
Vaxcyte made up 1.32% of Eventide Asset Management's portfolio in Q1 2026, its #15 holding.
Eventide Asset Management first reported a position in Vaxcyte in Q3 2023 and has held it in 11 quarters since.
336 funds tracked by Wall St. Rank held Vaxcyte as of Q1 2026.

Based on Eventide Asset Management's 13F filing for Q1 2026, filed 15 May 2026.